Literature DB >> 22926196

Experiences of parents and patients with the timing of Mucopolysaccharidosis type I (MPS I) diagnoses and its relevance to the ethical debate on newborn screening.

Minke H de Ru1, Machtelt G Bouwman, Frits A Wijburg, Myra C B van Zwieten.   

Abstract

INTRODUCTION: Newborn screening (NBS) techniques have been developed for several lysosomal storage disorders (LSDs), including Mucopolysaccharidosis type I (MPS I). MPS I is an LSD with a wide phenotypic spectrum that ranges from the severe Hurler phenotype to the attenuated Scheie phenotype. To improve the ethical discussion about NBS for MPS I, we performed an interview study to explore the experiences of MPS I patients and their parents with the timings of their diagnoses.
METHODS: We used a qualitative research approach consisting of 17 interviews with the parents of patients with all MPS I phenotypes and with patients with attenuated forms of MPS I. The interviews were audio-recorded, transcribed and subsequently analyzed to identify the main themes identified by the participants.
RESULTS: Five important themes, focusing on the experienced disadvantages of delayed diagnosis and the advantages and disadvantages of a hypothetical earlier diagnosis, were identified in our group of participants: 1) delayed diagnosis causing parental frustration, 2) delayed diagnosis causing patient frustration, 3) early diagnosis enabling reproductive decision-making, 4) early diagnosis enabling focusing on the diagnosis, and 5) early diagnosis enabling timely initiation of treatment. There was a remarkable similarity in the experiences with timing of diagnosis between parents of patients with the severe and the attenuated forms.
CONCLUSION: This was the first study to explore the personal experiences of MPS I patients and their parents with diagnostic timing. Our study identified five important themes that are highly relevant to the ethical discussion on expanding NBS programs for MPS I.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22926196     DOI: 10.1016/j.ymgme.2012.08.008

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  13 in total

1.  Newborn Screening for Lysosomal Storage Disorders: Views of Genetic Healthcare Providers.

Authors:  Emily C Lisi; Shawn E McCandless
Journal:  J Genet Couns       Date:  2015-08-29       Impact factor: 2.537

2.  Newborn screening for Pompe disease: impact on families.

Authors:  B Pruniski; E Lisi; N Ali
Journal:  J Inherit Metab Dis       Date:  2018-03-28       Impact factor: 4.982

3.  An algorithm to predict phenotypic severity in mucopolysaccharidosis type I in the first month of life.

Authors:  Sandra D K Kingma; Eveline J Langereis; Clasine M de Klerk; Lida Zoetekouw; Tom Wagemans; Lodewijk IJlst; Ronald J A Wanders; Frits A Wijburg; Naomi van Vlies
Journal:  Orphanet J Rare Dis       Date:  2013-07-09       Impact factor: 4.123

4.  Child and family experiences with inborn errors of metabolism: a qualitative interview study with representatives of patient groups.

Authors:  Sara D Khangura; Kylie Tingley; Pranesh Chakraborty; Doug Coyle; Jonathan B Kronick; Anne-Marie Laberge; Julian Little; Fiona A Miller; John J Mitchell; Chitra Prasad; Shabnaz Siddiq; Komudi Siriwardena; Rebecca Sparkes; Kathy N Speechley; Sylvia Stockler; Yannis Trakadis; Brenda J Wilson; Kumanan Wilson; Beth K Potter
Journal:  J Inherit Metab Dis       Date:  2015-07-25       Impact factor: 4.982

5.  The diagnostic journey of patients with mucopolysaccharidosis I: A real-world survey of patient and physician experiences.

Authors:  Stefano Bruni; Christine Lavery; Alexander Broomfield
Journal:  Mol Genet Metab Rep       Date:  2016-08-02

6.  Experiences of caregivers of children with inherited metabolic diseases: a qualitative study.

Authors:  Shabnaz Siddiq; Brenda J Wilson; Ian D Graham; Monica Lamoureux; Sara D Khangura; Kylie Tingley; Laure Tessier; Pranesh Chakraborty; Doug Coyle; Sarah Dyack; Jane Gillis; Cheryl Greenberg; Robin Z Hayeems; Shailly Jain-Ghai; Jonathan B Kronick; Anne-Marie Laberge; Julian Little; John J Mitchell; Chitra Prasad; Komudi Siriwardena; Rebecca Sparkes; Kathy N Speechley; Sylvia Stockler; Yannis Trakadis; Sarah Wafa; Jagdeep Walia; Kumanan Wilson; Nataliya Yuskiv; Beth K Potter
Journal:  Orphanet J Rare Dis       Date:  2016-12-07       Impact factor: 4.123

7.  Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications.

Authors:  Gé-Ann Kuiper; Olga L M Meijer; Eveline J Langereis; Frits A Wijburg
Journal:  Orphanet J Rare Dis       Date:  2018-01-08       Impact factor: 4.123

Review 8.  Newborn screening in mucopolysaccharidoses.

Authors:  Maria Alice Donati; Elisabetta Pasquini; Marco Spada; Giulia Polo; Alberto Burlina
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

Review 9.  Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder.

Authors:  Frits A Wijburg; Grzegorz Węgrzyn; Barbara K Burton; Anna Tylki-Szymańska
Journal:  Acta Paediatr       Date:  2013-02-06       Impact factor: 2.299

Review 10.  Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology.

Authors:  Christiane S Hampe; Julie B Eisengart; Troy C Lund; Paul J Orchard; Monika Swietlicka; Jacob Wesley; R Scott McIvor
Journal:  Cells       Date:  2020-08-05       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.